Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Tau biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

Aggregates of hyperphosphorylated tau (PHF-tau), such as neurofibrillary tangles, are linked to the degree of cognitive impairment in Alzheimer's disease. We have developed a novel PHF-tau targeting positron emission tomography imaging agent, [F-18]-T807, which may be useful for imaging Alzheimer's disease and other tauopathies. Here in, we describe the first human brain images with [F-18]-T807.

What this study adds

Evidence grade: Not rated

The authors describe the first human brain images with [F-18]-T807, a PET imaging agent they developed to target aggregated tau (PHF-tau). They say it may be useful for imaging Alzheimer's disease and other tauopathies.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M., et al. (2013). Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-122059

Vancouver

Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su M, et al. Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807. Journal of Alzheimer s Disease. 2013. doi:10.3233/jad-122059. PMID: 23234879.

BibTeX

@article{chien2013-23234879,
  author  = {Chien, David T. and Bahri, Shadfar and Szardenings, Anna Katrin and Walsh, Joseph C. and Mu, Fanrong and Su, Min‐Ying and Shankle, William Rodman and Elizarov, Arkadij M. and Kolb, Hartmuth Christian},
  title   = {{Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807}},
  journal = {Journal of Alzheimer s Disease},
  year    = {2013},
  doi     = {10.3233/jad-122059},
  pmid    = {23234879},
  url     = {https://doi.org/10.3233/jad-122059}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 9 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Why it matters

The authors describe the first human brain images with [F-18]-T807, a PET imaging agent they developed to target aggregated tau (PHF-tau). They say it may be useful for imaging Alzheimer's disease and other tauopathies.

How this study scored 48/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence left out, no data; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 6 of 6; Cited by studies here 0 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 46 of the 95 points it could be judged on, which is 48 of 100. Total 48 of 100.46 of the 95 points we could judge = 48 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 46 of the 95 points we could judge it on, which is 48 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease)
Journal's citation record 2 / 4 Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence — / 5 No evidence rating recorded — left out of this score
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2013 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 653 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 43.5 citations a year over 15 year(s) since 2013
Impact for its field and year 6 / 6 Cited 46.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 3 / 4 Cited 58 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Hartmuth Christian Kolb: h-index 65 (OpenAlex, whole career)
Institution's track record 1 / 3 University of California, Irvine: institution h-index 1,195 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 23234879)
Free to read 0 / 2 Behind a paywall — scores zero
Points 46 / 95 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 46 of the 95 points we could judge it on is 48 out of 100.
Total 48 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Tau biomarkers from nearby years

Also tagged “phosphorylated”

733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →